Video

ASCRS Live: Fortisite for corneal ulcers

Brian Shafer, MD, discussed Fortisite and the ability to treat corneal ulcers at the 2023 ASCRS annual meeting in San Diego.

Brian Shafer, MD, discussed Fortisite and the ability to treat corneal ulcers at the 2023 ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Brian Shafer, MD:

Hi, I'm Dr. Brian Shafer coming to you live from ASCRS 2023. I'm a cataract refractive cornea and glaucoma surgeon with the Schafer Vision Institute and I'm excited to talk to you about corneal ulcers.

We know that corneal ulcers are something that bogs down all of our clinics, It's usually that Friday at 5pm that walks through the door. And when a bad corneal ulcer comes through the door that's greater than one millimeter, central. And we know that we need to culture it and start fortified antibiotics. It's really difficult. The culturing piece is often done in our office. But when it comes time to get the fortified antibiotics, we're often sending our patients greater than an hour away, calling up this compounding pharmacy and trying to get this drug into their hands so that they can get it into their eye.

For the first time ever we have fortified antibiotics that we can stock on our shelves. Harrow Pharmaceutical now has Fortisite, which is fortified tobramycin and vancomycin. That we can stock on our shelves and dispense to our patients via a 503B pharmacy. And if that doesn't work out for you, you can do a 503A pharmacy and get it to them the very next day. We finally have the opportunity to treat these bad corneal ulcers, right in our clinics from the moment that we see them.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.